Navigation Links
UK is first to administer new anti-clotting technology

Volunteers at the Jack and Linda Gill Heart Institute at the University of Kentucky were the first ever to receive a new anti-clotting therapy. The drug and its antidote are being developed for their effectiveness in preventing blood clots while at the same time providing physicians the ability to rapidly reverse the effects of the blood thinner to help safeguard patients against uncontrolled bleeding.

More than 12 million patients are prescribed so-called "blood thinners" each year to prevent the formation of clots, which can block blood vessels, causing heart attacks, strokes and other debilitating or life-threatening conditions. Blood thinners, or antithrombotics, pose a risk of bleeding, particularly during surgery. The ability to stop the anti-clotting effects quickly could help protect patients from uncontrolled bleeding.

The Gill Heart Institute is one of two sites participating in the Phase 1 trial and is the first site to use the anti-clotting drug and its antidote.

This clinical trial will examine the drug's safety and tolerability in healthy volunteers as well as the antidote's ability to quickly reverse its effects. Although other new antithrombotics are undergoing testing in the U.S., this drug is believed to be the first of its kind.

"This class of drugs is a very promising technology that allows for the development of 'designer' drugs and their antidotes simultaneously," said Dr. Steven R. Steinhubl, the study's principal investigator at UK and director of cardiovascular education and clinical research at the Gill Heart Institute and a UK College of Medicine associate professor of cardiology. "It could have far-reaching implications."

"The research capacity of the cardiology division at UK has skyrocketed in the last year. Millions of dollars in research projects are under way, and we have attracted world-recognized leaders in drug discovery and development, such as Dr. Steinhubl. Leaders of technology and pharm aceutical companies have visited us in Lexington and are entrusting us to pioneer the next-generation of medicines and devices to improve healthcare," said Dr. David Moliterno, professor and vice chair of medicine, and chief, division of cardiovascular medicine, UK College of Medicine, and co-director of the UK Gill Heart Institute.

"Our goal is simple: we want to help patients with heart and vascular disorders by being at the forefront. Our research efforts are clearly bringing Kentuckians closer to the leading edge of the best medicine has to offer," Moliterno said.


'"/>

Source:University of Kentucky


Related biology news :

1. A genes first kiss sets off that affair known as puberty
2. Love at first smell
3. Worlds largest rainforest drying experiment completes first phase
4. PCRM develops worlds first cruelty-free insulin assay
5. Expression Project for Oncology (expO) completes first phase of standardized gene expression analyses
6. World-first Living Donor Islet Cell Transplant A Success; Procedure Offers Promise For Diabetics
7. DuPonts first biologically derived polymer receives global recognition
8. Anti cancer virotherapy well tolerated in first human administration, research finds
9. Unlike other mammals, newborn dolphins and orcas stay active 24/7 during first months of development
10. The first impact factor for PLoS Biology ?13.9
11. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... SARASOTA, FL (PRWEB) , ... ... ... Inc. (RPS®) today announces publication of a United States multicenter, prospective clinical ... single use, disposable, point-of-care diagnostic test capable of identifying clinically significant acute ...
(Date:10/11/2017)... LINDA, CA (PRWEB) , ... October 11, 2017 ... ... to upregulate any gene in its endogenous context, enabling overexpression experiments and avoiding ... (CRISPRa) system with small RNA guides is transformative for performing systematic gain-of-function studies. ...
(Date:10/11/2017)... HILLS, Calif. , Oct. 11, 2017  SkylineDx today ... (ICR) and University of Leeds ... risk-stratify patients with multiple myeloma (MM), in a multi-centric Phase ... University of Leeds is the sponsor ... and ICR will perform the testing services to include high-risk ...
(Date:10/10/2017)... , ... October 10, 2017 ... ... cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing ... HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with Children’s ...
Breaking Biology Technology: